This study showed that a radiomics signature of CD8 T-cells could predict lesion response and patient outcomes in melanoma patients treated with immunotherapy, highlighting the potential of radiomics to evaluate disease heterogeneity and patient prognosis. This evidence concerns the gene CD8A and melanoma.